An Overview of a Study of bb2121 in Multiple Myeloma

June 30, 2017
Sundar Jagannath, MDDS

Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses a first in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.